Evidence map›Paper›PMID 35345746›Full record

ArticleCureus2022

A Small Dose Can Cause a Major Problem.

Pooja Patel, Adriana Yates Munar, George Michel

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Pooja PatelEmergency Department, VA Medical Health Care System, Milwaukee, USA.
Adriana Yates MunarInternal Medicine, Larkin Community Hospital, South Miami, USA.
George MichelInternal Medicine, Larkin Community Hospital, South Miami, USA.
American Transmission Company (United States) · USLarkin Community Hospital · USMilwaukee VA Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Baclofen is a presynaptic gamma-aminobutyric acid agonist, which has been used to treat muscle spasms. Due to its low cost and low addiction potential, baclofen has been the muscle relaxant of choice for many years. This drug is metabolized in the kidneys, posing a threat to patients with underlying renal dysfunction, with complications ranging from drug toxicity to death. We present a case of baclofen toxicity in a patient with renal failure on hemodialysis, who presented with signs and symptoms of baclofen overdose after consuming 10 mg of the medication. The highlight of this case is the detailed history taking, verifying all home medications, and thorough physical examination of the patient.

Indexed as

baclofenbaclofen toxicityckddialysisdrug overdosemultivessel coronary artery disease (mvcad)overdose preventionpain controlsevere peripheral arterial diseaseside effects of medical treatment

Identifiers

PMID35345746
PMCPMC8956503
OpenAlexW4212822811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.